Clinical trial
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination…
NCT00001685 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001685 |
|---|---|
| Title | Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase |
| Official title | Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Neoplasm Metastasis |
| Intervention type | Biological |
| Interventions | Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase |
| Enrollment | 114 |
| Start date | Nov 1, 1997 |
| Completion | Sep 1, 2000 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: